SETD2 and acute myeloid leukemia: In addition, we identified 10.5% of 11q23/KMT2A‐rearranged pediatric AML patients carried SETD2 mutations as opposed to only 1.4% of patients without 11q23/KMT2A‐rearrangements and SETD2 mutations were more prevalent in patients with t(10;11)(p12;q23).